Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
AGEN

AGEN - Agenus Inc Stock Price, Fair Value and News

0.66USD-0.01 (-1.49%)Market Closed
Watchlist

Market Summary

USD0.66-0.01
Market Closed
-1.49%

AGEN Alerts

  • Point72 Asset Management, L.P. reported owning 6.8% of AGEN [2024-02-21]
  • 1 major insider buys recently.

AGEN Stock Price

View Fullscreen

AGEN RSI Chart

AGEN Valuation

Market Cap

251.8M

Price/Earnings (Trailing)

-4

Price/Sales (Trailing)

2.5

EV/EBITDA

-1.83

Price/Free Cashflow

-0.99

AGEN Price/Sales (Trailing)

AGEN Profitability

Operating Margin

89.55%

EBT Margin

-119.62%

Return on Equity

-3.54%

Return on Assets

-18.74%

Free Cashflow Yield

-101.36%

AGEN Fundamentals

AGEN Revenue

Revenue (TTM)

100.9M

Rev. Growth (Yr)

6.77%

Rev. Growth (Qtr)

-3.88%

AGEN Earnings

Earnings (TTM)

-62.9M

Earnings Growth (Yr)

-13.78%

Earnings Growth (Qtr)

12.12%

Breaking Down AGEN Revenue

Last 7 days

-12%

Last 30 days

3.1%

Last 90 days

-4.3%

Trailing 12 Months

-70.3%

How does AGEN drawdown profile look like?

AGEN Financial Health

Current Ratio

0.63

Debt/Equity

0.01

Debt/Cashflow

-18.17

AGEN Investor Care

Shares Dilution (1Y)

22.82%

Diluted EPS (TTM)

-0.8

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202395.0M99.4M100.9M0
2022309.9M320.1M89.9M98.0M
202184.8M68.5M306.7M295.7M
202085.3M96.5M91.4M88.2M
2019115.0M114.9M122.0M150.0M
201841.4M39.8M38.3M36.8M
201743.6M41.2M40.1M42.9M
201626.8M27.0M24.6M22.6M
201510.2M13.5M18.8M24.8M
20142.7M4.9M5.8M7.0M
20133.7M3.9M3.7M3.0M
201215.5M15.3M15.5M16.0M
20113.1M3.1M3.1M2.8M
20103.3M3.3M3.4M3.4M
20090003.3M

Tracking the Latest Insider Buys and Sells of Agenus Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 23, 2024
armen garo h
acquired
14,834
0.68
21,815
see remarks
Feb 15, 2024
armen garo h
bought
324,050
0.6481
500,000
see remarks
Feb 09, 2024
armen garo h
acquired
14,833
0.75
19,778
see remarks
Jan 26, 2024
armen garo h
acquired
14,833
0.66
22,475
see remarks
Jan 12, 2024
armen garo h
acquired
14,833
0.64
23,177
see remarks
Dec 29, 2023
armen garo h
acquired
19,466
0.83
23,453
see remarks
Dec 15, 2023
armen garo h
acquired
16,182
0.69
23,453
see remarks
Dec 01, 2023
armen garo h
acquired
16,167
0.78
20,727
see remarks
Nov 17, 2023
armen garo h
acquired
16,222
0.69
23,511
see remarks
Nov 15, 2023
hirsch susan b
acquired
3,750
0.75
5,000
-

1–10 of 50

Which funds bought or sold AGEN recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 28, 2024
AMERICAN INTERNATIONAL GROUP, INC.
added
8.36
-40,709
156,827
-%
Feb 26, 2024
Virtu Financial LLC
new
-
213,000
213,000
0.02%
Feb 20, 2024
READYSTATE ASSET MANAGEMENT LP
added
14.29
-324,370
1,669,700
0.06%
Feb 16, 2024
GSA CAPITAL PARTNERS LLP
added
1,891
1,851,000
1,987,000
0.17%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
added
3.92
-61,000
195,000
-%
Feb 15, 2024
BARCLAYS PLC
reduced
-32.39
-514,000
505,000
-%
Feb 15, 2024
Legal & General Group Plc
added
0.78
-94,948
267,938
-%
Feb 15, 2024
Front Row Advisors LLC
unchanged
-
-30.00
83.00
-%
Feb 15, 2024
WEXFORD CAPITAL LP
new
-
20,557
20,557
-%
Feb 15, 2024
GTS SECURITIES LLC
reduced
-89.26
-222,475
19,008
-%

1–10 of 43

Are Funds Buying or Selling AGEN?

Are funds buying AGEN calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own AGEN
No. of Funds

Unveiling Agenus Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 21, 2024
point72 asset management, l.p.
6.8%
28,268,112
SC 13G
Feb 14, 2024
deep track capital, lp
8.31%
31,697,539
SC 13G/A
Feb 13, 2024
vanguard group inc
7.93%
30,266,890
SC 13G/A
Feb 09, 2024
artal international s.c.a.
4.1%
15,631,235
SC 13G/A
Jan 25, 2024
blackrock inc.
8.5%
32,236,488
SC 13G/A
Jan 22, 2024
state street corp
2.28%
8,680,267
SC 13G/A
Feb 14, 2023
deep track capital, lp
8.86%
2.7e+07
SC 13G/A
Feb 09, 2023
state street corp
7.42%
22,603,650
SC 13G/A
Feb 09, 2023
vanguard group inc
7.97%
24,281,255
SC 13G/A
Feb 03, 2023
blackrock inc.
8.3%
23,400,423
SC 13G/A

Recent SEC filings of Agenus Inc

View All Filings
Date Filed Form Type Document
Feb 29, 2024
DEFA14A
DEFA14A
Feb 27, 2024
4
Insider Trading
Feb 26, 2024
DEF 14A
DEF 14A
Feb 21, 2024
SC 13G
Major Ownership Report
Feb 15, 2024
4
Insider Trading
Feb 15, 2024
8-K
Current Report
Feb 15, 2024
PRE 14A
PRE 14A
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 13, 2024
SC 13G/A
Major Ownership Report
Feb 12, 2024
4
Insider Trading

Peers (Alternatives to Agenus Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
36.3B
6.8B
-16.59% -47.80%
-7.7
5.3
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
19.2B
1.8B
-23.99% -31.71%
-43.66
10.51
76.23% 61.08%
16.4B
2.4B
-4.89% -18.90%
98.05
6.79
15.42% 18.43%
13.3B
3.7B
-7.62% -26.87%
22.19
3.59
8.87% 75.42%
MID-CAP
7.7B
396.6M
-2.06% 34.31%
-14.57
19.42
425.83% 18.94%
6.3B
-
-3.85% 226.12%
-10.06
60.35
54.84% -25.61%
4.5B
240.7M
-19.08% -10.99%
-15.05
18.56
-1.03% -92.09%
4.0B
726.4M
-12.60% 32.37%
-64.55
5.45
40.45% 71.62%
3.9B
270.6M
8.92% 47.81%
-16.3
14.41
440.80% -27.84%
SMALL-CAP
2.0B
398.2M
-3.38% -9.50%
28.08
5.03
85.90% -14.05%
752.9M
983.7M
-9.17% -57.89%
-1.38
0.77
-50.36% 17.16%
217.0M
4.9M
-14.18% -58.18%
-1.32
44.39
-57.57% 50.48%
154.8M
881.7K
289.54% 381.25%
-3.26
112.79
-77.61% -13.74%
4.3M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Agenus Inc News

Latest updates
AmericanBankingNEWS22 hours ago
InvestorsObserver23 Feb 202402:51 pm
InvestorsObserver06 Feb 202408:00 am

Agenus Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue-3.9%24,314,00025,296,00022,902,00028,385,50022,772,00020,926,00025,941,00020,261,000252,954,00010,730,00011,719,00031,265,00014,832,00026,945,00015,128,00034,502,00019,940,00015,715,00079,891,0006,451,00012,802,000
Cost Of Revenue19.3%303,000254,0002,294,0007,693,000308,0002,024,000543,000881,000817,000667,0001,105,000-911,000634,000-------
  S&GA Expenses-7.4%18,909,00020,415,00018,237,00025,035,50018,105,00018,914,00018,953,00021,971,50021,385,00016,650,00016,352,00020,030,00014,380,00014,195,00010,613,00012,318,50011,512,00011,405,00010,805,0009,724,0009,203,000
  R&D Expenses-13.2%51,443,00059,285,00057,118,00053,278,50046,011,00044,960,00042,442,00053,486,00042,937,00045,508,00036,677,00035,569,50032,134,00038,550,00036,363,00036,833,50046,132,00045,243,00040,130,00036,031,00029,854,000
EBITDA Margin3.1%-1.07-1.10-1.17-1.15-1.26-0.35-0.36-0.38-0.37-1.64-1.32----------
Interest Expenses-5.5%827,000875,000830,000296,000279,000289,000279,000290,000285,000299,000278,000284,000302,000386,000204,000299,000305,000308,000312,000333,000283,000
EBT Margin1.5%-1.20-1.21-1.27-1.23-1.34-0.38-0.39-0.41-0.39-1.76-1.42----------
Net Income12.1%-64,532,000-73,430,000-70,893,000145,972,000-56,715,000-49,235,000-50,604,000-67,607,000177,277,000-83,991,000-54,403,000-37,660,000-51,646,000-48,244,000-45,271,000-30,107,000-45,526,000-50,686,00018,454,000-47,807,000-33,177,000
Net Income Margin-12.5%-0.62-0.55-0.33-0.11-2.490.03-0.08-0.100.00-3.32-2.26----------
Free Cashflow-6.5%-68,683,000-64,480,000-60,368,000-61,684,000-47,911,000-61,905,000-56,935,000-31,889,000108,987,000-57,827,000-42,940,000----------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-12.5%335384413414429456441466438192235215204186180155175207246136130
  Current Assets-26.5%12617120621325128929033230893.0013611412510510387.0010713917975.0068.00
    Cash Equivalents902.9%10611.0015.0017920822824829225774.0011910011479.0092.0062.0093.0012215853.0046.00
  Inventory-----------------0.000.000.000.000.00
  Net PPE-2.6%14014314013310189.0076.0060.0050.0029.0027.0027.0027.0029.0028.0026.0025.0026.0026.0025.0026.00
  Goodwill-0.3%25.0025.0026.0025.0024.0024.0025.0025.0025.0025.0024.0025.0025.0024.0023.0023.0023.0023.0023.0023.0023.00
  Current Liabilities-2.8%19820419118917316016315715016913813014714212712213312210668.0058.00
  Long Term Debt0.4%13.0013.0013.0013.00---13.0013.0019.0019.0019.0019.0019.0013.0013.00---13.0013.00
    LT Debt, Current-37.8%0.001.001.001.0013.0014.0014.001.001.001.001.001.001.002.001.001.0014.0014.0014.000.000.00
    LT Debt, Non Current0.4%13.0013.0013.0013.00---13.0013.0019.0019.0019.0019.0019.0013.0013.00---13.0013.00
Shareholder's Equity1.5%1,7771,7511,7151,6451,61514.0028.0048.0036.001,3531,3291,2581,2271,1561,1321,0601,0551,0521,0441,0051,000
  Retained Earnings-5.6%-1,900-1,800-1,800-1,709-1,600-1,584-1,500-1,489-1,400-1,602-1,500-1,465-1,428-1,377-1,329-0.02-1,254-1,209-1,1589.00-1,129
  Additional Paid-In Capital1.5%1,7771,7511,7151,6451,6151,5831,5501,5201,4641,3531,3291,2581,2271,1561,1321,0601,0551,0521,0441,0051,000
Accumulated Depreciation3.9%61.0058.0056.0054.0053.0052.0052.0051.0049.0050.0048.0047.0046.0045.0044.0043.0042.0040.0039.0038.0037.00
Shares Outstanding----------216--186172148------
Minority Interest-15.9%14.0016.005.006.009.0010.0012.0013.00-6.30-8.63-8.29-7.83-7.83-7.34-6.58-5.98-5.18-4.38-3.15-2.08-0.98
Float------544---1,230---671---407---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations-8.6%-65,231-60,043-58,526-47,338-32,191-43,453-52,391-22,927131,373-55,557-42,744-35,590-31,626-37,375-34,505-31,780-66,08740,90076,587-35,800-24,600
  Share Based Compensation-2.7%5,8816,0425,4854,2594,4534,6344,9915,1984,7905,5884,0012,7442,7232,5532,3973,0483,0841,9171,8431,9301,905
Cashflow From Investing2133.7%11,548517-11,489-6,383-15,636-4,058-7,533-13,299-27,385-2,270-196-834-873-2,090-644-1,056-839-1,261-1,501-601-819
Cashflow From Financing-52.9%18,03838,26356,25023,77328,22327,79616,03871,60578,90511,79262,96224,64767,28326,31265,6131,26834.00-76.0030,09743,42828,494
  Buy Backs-120.5%-893-405-------------------

AGEN Income Statement

2023-09-30
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenue:    
Total revenues$ 24,314$ 22,772$ 72,513$ 69,638
Operating expenses:    
Cost of service revenue(303)(308)(2,851)(2,875)
Research and development(51,443)(46,011)(167,846)(133,412)
General and administrative(18,909)(18,105)(57,562)(55,971)
Contingent purchase price consideration fair value adjustment 7398950
Operating loss(46,341)(41,645)(155,348)(121,670)
Other income (expense):    
Non-operating income4425372389,654
Interest expense, net(18,633)(15,607)(53,745)(44,538)
Net loss(64,532)(56,715)(208,855)(156,554)
Dividends on Series A-1 convertible preferred stock(53)(53)(160)(159)
Less: net loss attributable to non-controlling interest(2,331)(2,493)(9,384)(7,573)
Net loss attributable to Agenus Inc. common stockholders$ (62,254)$ (54,275)$ (199,631)$ (149,140)
Per common share data:    
Basic net loss attributable to Agenus Inc. common stockholders$ (0.16)$ (0.19)$ (0.57)$ (0.54)
Diluted net loss attributable to Agenus Inc. common stockholders$ (0.16)$ (0.19)$ (0.57)$ (0.54)
Weighted average number of Agenus Inc. common shares outstanding:    
Basic378,152286,854349,167274,170
Diluted378,152286,854349,167274,170
Other comprehensive loss:    
Foreign currency translation loss$ (311)$ (1,505)$ (1,943)$ (848)
Other comprehensive loss(311)(1,505)(1,943)(848)
Comprehensive loss(62,565)(55,780)(201,574)(149,988)
Research and Development [Member]    
Revenue:    
Total revenues3,4144,5738,51513,220
Royalty Sales Milestone [Member]    
Revenue:    
Total revenues 7,934 25,250
Service Revenue [Member]    
Revenue:    
Total revenues5401,0412,4644,167
Non-Cash Royalty Revenue Related to the Sale of Future Royalties [Member]    
Revenue:    
Total revenues$ 20,360$ 9,224$ 61,534$ 27,001

AGEN Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
ASSETS  
Cash and cash equivalents$ 106,305$ 178,674
Short-term investments 14,684
Accounts receivable1,0302,741
Prepaid expenses15,88613,829
Other current assets2,3293,194
Total current assets125,550213,122
Property, plant and equipment, net of accumulated amortization and depreciation of $60,750 and $54,075 at September 30, 2023 and December 31, 2022, respectively139,679133,017
Operating lease right-of-use assets30,01831,269
Goodwill24,66625,467
Acquired intangible assets, net of accumulated amortization of $17,444 and $16,148 at September 30, 2023 and December 31, 2022, respectively4,4976,228
Other long-term assets11,0624,453
Total assets335,472413,556
LIABILITIES AND STOCKHOLDERS' DEFICIT  
Current portion, long-term debt387575
Current portion, liability related to sale of future royalties and milestones98,50083,510
Current portion, deferred revenue4,99412,269
Current portion, operating lease liabilities2,5591,943
Accounts payable40,87140,939
Accrued liabilities37,62938,259
Other current liabilities13,41611,457
Total current liabilities198,356188,952
Long-term debt, net of current portion12,72012,584
Liability related to sale of future royalties and milestones, net of current portion167,070187,753
Deferred revenue, net of current portion1,1431,143
Operating lease liabilities, net of current portion63,16663,326
Other long-term liabilities8,30914,700
Commitments and contingencies
STOCKHOLDERS' (DEFICIT) EQUITY  
Common stock, par value $0.01 per share; 800,000,000 shares authorized; 381,381,803 and 305,573,397 shares issued at September 30, 2023 and December 31, 2022, respectively3,8143,056
Additional paid-in capital1,777,4801,644,658
Accumulated other comprehensive income (loss)(1,028)915
Accumulated deficit(1,909,378)(1,709,907)
Total stockholders' deficit attributable to Agenus Inc.(129,112)(61,278)
Non-controlling interest13,8206,376
Total stockholders' deficit(115,292)(54,902)
Total liabilities and stockholders' deficit335,472413,556
Series A-1 convertible preferred stock [Member]  
STOCKHOLDERS' (DEFICIT) EQUITY  
Series A-1 convertible preferred stock; 31,620 shares designated, issued, and outstanding at September 30, 2023 and December 31, 2022; liquidation value of $33,833 at September 30, 2023$ 0$ 0
AGEN
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 2 clinical trial; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; BMS-986442, a TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, it develops INCAGN1876, a GITR monospecific antibody; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
 CEO
 WEBSITEwww.agenusbio.com
 EMPLOYEES533

Agenus Inc Frequently Asked Questions


What is the ticker symbol for Agenus Inc? What does AGEN stand for in stocks?

AGEN is the stock ticker symbol of Agenus Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Agenus Inc (AGEN)?

As of Fri Mar 01 2024, market cap of Agenus Inc is 251.79 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AGEN stock?

You can check AGEN's fair value in chart for subscribers.

What is the fair value of AGEN stock?

You can check AGEN's fair value in chart for subscribers. The fair value of Agenus Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Agenus Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AGEN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Agenus Inc a good stock to buy?

The fair value guage provides a quick view whether AGEN is over valued or under valued. Whether Agenus Inc is cheap or expensive depends on the assumptions which impact Agenus Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AGEN.

What is Agenus Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Mar 01 2024, AGEN's PE ratio (Price to Earnings) is -4 and Price to Sales (PS) ratio is 2.5. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AGEN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Agenus Inc's stock?

In the past 10 years, Agenus Inc has provided -0.141 (multiply by 100 for percentage) rate of return.